07:56 AM EDT, 07/31/2025 (MT Newswires) -- Eli Lilly ( LLY ) said Thursday that its diabetes drug Mounjaro showed a "definitive cardiovascular benefit" in a head-to-head phase 3 study comparing it with its older diabetes drug Trulicity in adults with type 2 diabetes and atherosclerotic cardiovascular disease.

"These findings strengthen the case for Mounjaro as a potential front-line treatment for people with type 2 diabetes and cardiovascular disease," said Kenneth Custer, executive vice president and president, Lilly Cardiometabolic Health.

Shares of Eli Lilly ( LLY ) were down more than 2% in recent premarket activity Thursday.